Biotechnology in China – regulation, investment, and delayed commercialization

China has been investing heavily in biotechnology to increase agricultural productivity. While a number of Chinese developed GM crops have cleared the required scientific hurdles – some more than a decade ago – commercialization has not been approved. The regulatory regime for GMOs in China is relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Zhihua, Kerr, William A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090284/
https://www.ncbi.nlm.nih.gov/pubmed/35506348
http://dx.doi.org/10.1080/21645698.2022.2068336
Descripción
Sumario:China has been investing heavily in biotechnology to increase agricultural productivity. While a number of Chinese developed GM crops have cleared the required scientific hurdles – some more than a decade ago – commercialization has not been approved. The regulatory regime for GMOs in China is relatively less well understood than that of the US or the EU. This paper provides a systematic overview of China’s regulatory regime, R&D investment and delayed commercialization decisions on biotechnology over the last 40 years and draws some conclusions regarding the likelihood of the commercialization for major GM crops in the future.

Ejemplares similares